Tenderwize
Wróć do wyszukiwania

Open-house drug rebate agreements Brandenburg

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 133 days left·Open·Supplies
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Brandenburg

57/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

57 / 100

Złożoność

61 / 100

Czynniki ryzyka

The lot descriptions state a latest contract-conclusion date of 21 February 2026, whereas the structured/XML deadline i...

No estimated value, quantities, expected demand or guaranteed volume is disclosed in the provided data, so potential re...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Najważniejsze informacje

Zamawiający
AOK Nordost - Die Gesundheitskasse
Kraj
Niemcy
CPV
33600000 - Pharmaceutical products
Termin
Feb 21, 2027

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 3 lots
  • Duration until Apr 2027
  • Conclusion of non-exclusive drug discount agreements under Section 130a(8c) SGB V for the Brandenburg statutory health-insurance region.
  • Supply-related scope covering pharmacy-prepared parenteral oncology preparations made from finished medicinal products for immediate physician administration to patients.
Pokaż pełne podsumowanie

Open-house pharmaceutical discount agreements under Section 130a(8c) SGB V for the Brandenburg statutory health-insurance region, covering Bevacizumab, Rituximab and Trastuzumab. The buyer states that every interested pharmaceutical company meeting the published requirements may join on identical, non-negotiable terms and that no supplier selection is made. Contracts are planned from 1 May 2026 to 30 April 2027, subject to earlier termination or automatic suspension if a relevant nationwide or regional discount agreement enters into force. Procurement documents are referenced through the DTVP portal but were not provided for analysis. The structured final deadline is 21 February 2027, while the lot descriptions state that contract conclusion is possible only until 21 February 2026; this material inconsistency must be clarified.

Ryzyka

The lot descriptions state a latest contract-conclusion date of 21 February 2026, whereas the structured/XML deadline i...

No estimated value, quantities, expected demand or guaranteed volume is disclosed in the provided data, so potential re...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Only pharmaceutical companies may participate as potential contract partners.
  • The contract terms are pre-established, identical and not individually negotiable.

Administrative

  • The completed and signed agreement must be submitted together with the completed PZN file named OHV_8c_Brandenburg_Festlegung_[Wirkstoffname]_PZN.

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Potsdam, DEU

Identyfikator

DE275390265

Działalność

Health

Części (3)

LOT-0001

Bevacizumab

Open-house, non-exclusive pharmaceutical discount agreement for Bevacizumab (ATC L01FG01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Lokalizacja

Germany

Czas trwania

Apr 2026 - Apr 2027

Kategoria

Pharmaceutical products

Termin

Deadline Feb 21, 2027

LOT-0002

Rituximab

Open-house, non-exclusive pharmaceutical discount agreement for Rituximab (ATC L01FA01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Lokalizacja

Germany

Czas trwania

Apr 2026 - Apr 2027

Kategoria

Pharmaceutical products

Termin

Deadline Feb 21, 2027

LOT-0003

Trastuzumab

Open-house, non-exclusive pharmaceutical discount agreement for Trastuzumab (ATC L01FD01), concerning pharmacy-prepared parenteral oncology preparations from finished medicinal products for immediate physician administration to patients in the Brandenburg region. The agreement is offered to all eligible interested pharmaceutical companies on identical non-negotiable terms.

SuppliesEU fundedElectronic submission

Lokalizacja

Germany

Czas trwania

Apr 2026 - Apr 2027

Kategoria

Pharmaceutical products

Termin

Deadline Feb 21, 2027

Szczegóły zamówienia

Data publikacji
11 Feb 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
100552-2026

Dokumenty (2)

Podobne przetargi